Genfit Names Pejvack Motlagh as Chief Medical Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 28 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Appointment Announcement: Genfit has appointed Pejvack Motlagh as its new Chief Medical Officer.
Professional Background: Motlagh brings over 20 years of experience in the pharmaceutical and biotechnology sectors, having previously served as CMO at Egle Therapeutics and Mablink Biosciences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
